Organization | Jacobus Pharmaceutical

Jacobus Pharmaceutical Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3

Founded: Princeton NJ United States (1977)

Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial

1996

NCT00429533

First Marketed Drug

1979

dapsone (aczone)

First NDA Approval

1979

dapsone (aczone)

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Jacobus | JACOBUS | JACOBUS PHARM CO INC

Active Ingredients

Marketed Drugs (3)

amifampridine phosphate (firdapse) (2022)

aminosalicylic acid (Paser) (1994)

dapsone (aczone) (1979 NDA)

Drugs in Phase 3 Trials (6)

clindamycin (cleocin) (1 trial)

dapsone (aczone) (7 trials)

pentamidine (pentam) (1 trial)

primaquine (1 trial)

sulfamethoxazole (gantanol) (3 trials)

trimethoprim (3 trials)

Drugs in Phase 2 Trials (2)

amifampridine phosphate (firdapse) (6 trials)

aminosalicylic acid (Paser) (2 trials)

Drugs in Phase 1 Trials (2)

leucovorin (1 trial)

trimetrexate (neutrexin) (1 trial)

Indications

Approved Indications

Dermatitis Herpetiformis

Purpura, Thrombocytopenic, Idiopathic

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 1)

Communicable Diseases (Phase 1)

Crohn Disease (Phase 2)

HIV Infections (Phase 1)

Infections (Phase 1)

Lambert-Eaton Myasthenic Syndrome (Phase 2)

Pemphigus (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Pneumocystis (Phase 3)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 15
# of Trial APIs: 10